• Check Our Services
From Data to Discovery Africa's Amyloidosis Research Hub

My Account

LOG IN
open-navigation
close-navigation
JOIN US

The Best Help in Services & ai medical

Transthyretin (ATTR) cardiac amyloidosis is a progressive infiltrative cardiomyopathy caused by the deposition of misfolded transthyretin (TTR) protein within the myocardium. Effective treatment requires a dual strategy:

01

Disease-modifying therapies

targeting the underlying TTR protein cascade

02

Supportive cardiac management

to control heart failure and conduction complications

Early diagnosis is critical, as disease-modifying therapies are most effective before advanced structural damage occurs.

Understanding the Therapeutic Targets

ATTR cardiomyopathy develops through a multistep biological cascade:

 

1

TTR gene transcription

2

TTR monomer production

3

Tetramer dissociation

4

Misfolded monomers

5

Amyloid fibril formation

6

Tissue deposition in the heart and nerves

Modern therapies intervene at different stages of this pathway.

1. Inhibition of TTR Production (Gene Silencing & Editing)

These therapies reduce hepatic production of transthyretin, lowering circulating TTR levels and slowing amyloid formation.

RNA Interference (RNAi)

  • Patisiran

  • Vutrisiran

These small interfering RNA therapies target TTR mRNA in hepatocytes, significantly reducing serum TTR levels.

Antisense Oligonucleotides (ASO)

  • Inotersen

  • Eplontersen

These inhibit TTR mRNA translation, reducing protein synthesis.

Gene Editing

  • CRISPR-Cas9 (e.g., Nexiguran Ziclumeran)

Emerging therapies aim to permanently silence the TTR gene through in vivo genome editing.

Liver Transplantation

Historically used in hereditary ATTR (hATTR), liver transplantation removes the primary source of mutant TTR production. However, it is now less common due to targeted pharmacologic therapies.

2. Transthyretin Tetramer Stabilization

Tetramer dissociation is the rate-limiting step in amyloid formation. Stabilizers bind TTR and prevent dissociation into misfolded monomers.

 

Approved and Investigational Stabilizers

  • Tafamidis (standard of care in ATTR-CM)

  • Diflunisal

  • Acoramidis (AG10)

  • Tolcapone

 

Tafamidis has demonstrated mortality and hospitalization benefits in ATTR-CM and is currently the cornerstone disease-modifying therapy.

3. Removal of Misfolded Transthyretin

Emerging therapies aim to enhance the clearance of circulating misfolded TTR species.

  • PRX004 (investigational monoclonal antibody)

These therapies seek to neutralize toxic TTR aggregates before tissue deposition.

4. Removal of Amyloid Deposits

Therapies targeting established amyloid fibrils aim to reverse organ dysfunction.

  • PRX004 (dual mechanism potential)

  • Doxycycline + TUDCA (investigational approach)

Amyloid removal remains an area of active research and represents a promising future direction.

Supportive Treatment of Cardiac Involvement

Even with disease-modifying therapy, most patients require careful cardiac management.

5. Heart Failure Management

Heart failure in ATTR-CM is predominantly restrictive with preserved or mildly reduced ejection fraction.

 

Key Principles:

  • Careful fluid management

  • Loop diuretics as first-line therapy

  • Mineralocorticoid receptor antagonists when tolerated

  • Avoid excessive preload reduction

 

Caution:

  • ACE inhibitors, ARBs, and beta-blockers are often poorly tolerated due to low stroke volume.

  • Calcium channel blockers and digoxin should generally be avoided due to potential toxicity in amyloid hearts.

 

Anticoagulation

Atrial fibrillation is common and carries a high thromboembolic risk. Anticoagulation is often recommended regardless of CHA₂DS₂-VASc score.

6. Conduction System Disease Management

ATTR frequently affects the conduction system.

 

Management includes:

  • Pacemaker implantation for symptomatic bradycardia or AV block

  • Individualized decision-making for ICD placement

  • Consideration of CRT in selected patients

 

Electrophysiologic monitoring is essential due to progressive conduction abnormalities.

7. Advanced Supportive Therapies

Heart Transplantation

May be considered in carefully selected patients, particularly younger individuals with hereditary disease.

 

Combined Heart–Liver Transplantation

Rare but considered in selected hereditary cases.

 

Mechanical Circulatory Support

Left ventricular assist devices (LVAD) have limited use due to restrictive physiology but may be considered in specific contexts.

Personalized and Multidisciplinary Care

Management of ATTR cardiac amyloidosis requires coordination between:

  • Cardiologists

  • Heart failure specialists

  • Neurologists

  • Geneticists

  • Electrophysiologists

  • Multidisciplinary amyloidosis clinics

Genetic testing is mandatory in all confirmed ATTR cases to distinguish:

  • Hereditary ATTR (hATTR)

  • Wild-type ATTR (wtATTR)

This distinction guides family screening and therapeutic strategy.

Treatment in the African Context

In Africa, treatment access remains unequal. Key priorities include:

  • Expanding diagnostic capacity

  • Improving access to disease-modifying therapies

  • Strengthening clinician education

  • Developing Africa-led registries and outcome data

  • Integrating ATTR into heart failure pathways

Early recognition of red flags, bilateral carpal tunnel syndrome, unexplained LV hypertrophy, apical sparing pattern on strain imaging, neuropathy, and low voltage ECG, can significantly improve outcomes.

Future Directions in ATTR Therapy

The therapeutic landscape is evolving rapidly:

  • Long-acting RNA therapies

  • Gene editing approaches

  • Amyloid-clearing antibodies

  • Combination therapy strategies

The future of ATTR treatment lies in earlier diagnosis, combination disease-modifying strategies, and equitable global access.

Key Takeaways

Rated 5 out of 5
  • ATTR cardiac amyloidosis is treatable, particularly when diagnosed early.
  • Tafamidis remains the cornerstone stabilizer therapy.
  • Gene-silencing therapies significantly reduce TTR production.
  • Supportive heart failure care remains essential.
  • Multidisciplinary management improves outcomes.
  • Africa must expand diagnostic and therapeutic access to reduce late-stage presentation.